Omalizumab safety in pregnancy

Francesca Levi-Schaffer*, David Mankuta

*Corresponding author for this work

Research output: Contribution to journalEditorial

5 Scopus citations
Original languageAmerican English
Pages (from-to)481-483
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Volume145
Issue number2
DOIs
StatePublished - Feb 2020

Bibliographical note

Funding Information:
We acknowledge the assistance of Fidan Rahimli Alekberli, MD, in discussions of the manuscript and the literature search. Dr Levi-Schaffer is affiliated with the Adolph and Klara Brettler Center at the Hebrew University. F.L.-S.’s research is funded partly by the Israel Science Foundation, Rosetrees Trust (United Kingdom), Aimwell Charitable Trust (United Kingdom), the United States–Israel Binational Science Foundation (BSF), and the Israel Ministry of Science and Technology.

Keywords

  • Omalizumab
  • drug safety
  • fetal malformations
  • placental transfer
  • pregnancy
  • preterm delivery
  • thrombocytopenia

Cite this